Raymond James analyst Jayson Bedford raised the firm’s price target on Merit Medical to $88 from $86 and keeps an Outperform rating on the shares. Merit Medical’s Q1 results were strong, and the two most important business drivers, organic revenue growth and gross margin, were well ahead of estimates, the analyst tells investors in a research note. The firm believes management has a clear line of sight into balanced growth.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MMSI:
- Merit Medical reports Q1 EPS 64c, consensus 55c
- Merit Medical Reports Results for First Quarter March 31, 2023
- Merit Medical price target raised to $84 from $78 at Needham
- Merit Medical price target raised to $86 from $80 at Raymond James
- Merit Medical Systems to Announce First Quarter 2023 Results on April 26, 2023